Johnson & Johnson plans to expand TB R&D in India
The company along with the government of India is working to bring the most impactable drug for tuberculosis - bedaquiline to people, said Executive Vice President Paul Stoffels of Johnson & Johnson.
Johnson and Johnson (J&J) is betting big on India. The pharma major's Executive Vice President Paul Stoffels told CNBC-TV18 that the company is planning to increase its tuberculosis-specific research in India.
At a time when Donald Trump is pursuing his Make in America policy, Stoffels said the US President's policy doesn't change much for his company.
He said, ”We continue to be focused on making a significant medical impact with the science we do and I trust it would be relevant for society and people will like it and need it.”
When asked where he saw India in terms of their research and development pipeline, he said the company has plans to expand their TB-specific R&D in India.
The company along with the government of India is working to bring the most impactable drug for tuberculosis - bedaquiline to people. Moreover, with launch of Invocana in India, which is an anti-diabetes drug they plan to make a significant contribution to the country.
Therefore, India is important and will be even more important for the company going forward, he said.
Last year, Telangana Government had said that it has entered into an MoU with Johnson & Johnson to work together for making the state tuberculosis free.
Earlier in a keynote address on his company's innovation landscape, Stoffels said there were 140 molecules in different stages of development. He also said the company has incubators for startups in USA and Canada and has place to expand globally.
Source:
CNBC
